The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Construction
  • Technology
  • Health
  • Entertainment
  • Marketing

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Imagen Golf Announces Strategic Partnership with The Back Nine of Yardley to Deliver World-Class Indoor Golf Instruction
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • WhereTu Launches to Help Americans Build Successful Lives Abroad
  • Alcom Printing Achieves SGP Recertification
  • John Marc Rittle Receives Pennsylvania's Most Influential Leaders Award
  • Appliance EMT Expands Built-In and Walk-In Refrigerator Service in Metro Atlanta
  • LawProactive Launches SB 37-Compliant Attorney Marketing Software With Exclusive City Territories Across California

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Lineus Medical Renews Agreement with Vizient, Delivering Enhanced Value for Vizient Members
  • Pittsburgh Divorce Attorney Candice L. Komar Elected Chair of PBA Family Law Section
  • Grace Montessori School Receives $30,000 from Payne Foundation and $12,000 from Trexler Trust to Sup
  • Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
  • Search Is Broken. Curated Discovery Is the Future
  • 20 Ways to Save Money Running a Van
  • How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
  • Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse
  • Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
  • New School Announces Student Enrollment
  • Able Rooter Expands Services to Offer Premium Water Heater Installation Across St. Louis
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • J. Kenton Pierce Wins Prometheus Award for Best Novel
  • Ezra Wohlgelernter Named as a 2026 Philadelphia Power Broker by City & State PA
  • Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
  • Brett Furman Launches Ranks Grow
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys

Popular on PennZone

  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
  • Turnstone Creative's Ashley Russo Serves as Emcee for United Way's 2026 NERC and Women's Summit
  • Top 5 Most Reliable Used Vans in the UK in 2026
  • Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
  • Freedomtech Solutions Launches the World's First Pre‑Installed Agentic AI Server — Instant, Sovereign, Infrastructure‑Native Intelligence
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Compton to host first Juneteenth celebration with We Are Us Festival
  • Custom Woodworker Launches Updated Website

Similar on PennZone

  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us